High Red Cell Count Symptoms: Causes, Signs & What to Do
High red cell count (erythrocytosis) is most commonly secondary -- the body responds to low oxygen with more red cells. Primary erythrocytosis (polycythemia vera) is a bone marrow disorder with JAK2 mutation and characteristic features including aquagenic pruritus and high thrombotic risk. This page covers the specific symptoms, likely causes, normal ranges, and when to act.
Red blood cells (RBCs) carry oxygen from the lungs to every tissue in the body via hemoglobin. High RBC count (erythrocytosis, above the reference range for sex) means more red cells than expected — which thickens the blood (raises viscosity) and impairs the smooth flow of blood through small vessels. Erythrocytosis can be relative (plasma volume shrinks, concentrating cells) or absolute (total red cell mass is genuinely increased). The clinical significance and workup differ significantly between these two categories. See the Red Cell Count biomarker overview for how the RBC count relates to hemoglobin and hematocrit.
What High Red Cell Count Means
The first step is determining whether erythrocytosis is relative or absolute:
- Relative erythrocytosis: plasma volume is reduced (dehydration, diuretics, burns) — the number of red cells is normal but they are concentrated in a smaller fluid volume; RBC count and hematocrit rise artificially; resolves with hydration
- Absolute erythrocytosis: true increase in red cell mass; confirmed by measuring total RBC mass (red cell mass study) or recognizing the clinical pattern
- Secondary (appropriate): hypoxia drives erythropoietin (EPO) production, which stimulates the bone marrow; altitude, COPD, sleep apnea, cyanotic heart disease
- Secondary (inappropriate): EPO is produced without hypoxia — EPO-producing tumors, exogenous EPO/anabolic steroids
- Primary (polycythemia vera): JAK2 V617F or exon 12 mutation causes EPO-independent red cell production; the bone marrow produces excess red cells, WBCs, and platelets
Symptoms of High Red Cell Count
Relative erythrocytosis (from dehydration):
- Thirst, decreased urine output
- Dizziness on standing (orthostatic hypotension)
- No other specific symptoms from the RBC elevation itself
Secondary erythrocytosis from hypoxia (the underlying disease drives symptoms):
- Chronic dyspnea, cough, wheezing (COPD or pulmonary disease)
- Cyanosis (bluish discoloration of lips and fingernails) in advanced disease
- Fatigue and exercise intolerance
- Snoring, morning headache, daytime sleepiness (sleep apnea)
Polycythemia vera (PV) — primary erythrocytosis:
- Aquagenic pruritus: itching after hot water exposure (shower or bath) — one of the most characteristic and specific symptoms; caused by histamine release from mast cells; present in up to 40% of PV patients and rare in secondary erythrocytosis; often precedes diagnosis by years
- Plethora: ruddy, reddish-purple complexion from engorged skin capillaries; particularly visible on the face
- Headache, dizziness, visual disturbances, ringing in the ears (from increased blood viscosity and reduced cerebral blood flow)
- Thrombosis: the most clinically significant PV complication; both arterial (stroke, TIA, MI) and venous (DVT, PE, unusual-site thrombosis — mesenteric vein, hepatic vein/Budd-Chiari syndrome, cerebral sinus thrombosis); these unusual-site thromboses are characteristic of myeloproliferative neoplasms
- Splenomegaly: the enlarged spleen causes left upper quadrant fullness, early satiety, and sometimes pain
- Gout: high cell turnover raises uric acid
- Erythromelalgia: burning pain and redness in hands and feet (also seen in essential thrombocythemia)
What Causes High Red Cell Count
Relative erythrocytosis (most benign):
- Dehydration (the most common cause of a mildly elevated RBC on routine labs)
- Stress erythrocytosis / Gaisböck syndrome: a pattern of mild absolute erythrocytosis in middle-aged obese hypertensive men with relatively low plasma volume; not a true pathological process
- Diuretic use, burns, vomiting, diarrhea — any cause of plasma volume contraction
Secondary absolute erythrocytosis (appropriate response to hypoxia):
- High-altitude residence: acclimatization response; reversible upon returning to sea level
- Chronic pulmonary disease: COPD, severe emphysema, pulmonary fibrosis with chronic hypoxia
- Obstructive sleep apnea: nocturnal hypoxia triggers EPO production; mild erythrocytosis; normalizes with CPAP therapy
- Cyanotic congenital heart disease: right-to-left shunting causes chronic hypoxemia
Secondary absolute erythrocytosis (inappropriate EPO):
- Renal cell carcinoma (most common EPO-producing tumor)
- Hepatocellular carcinoma
- Cerebellar hemangioblastoma (rare, but a classic association)
- Large uterine fibroids (EPO production by fibroid tissue)
- Exogenous EPO (doping in endurance athletes) or anabolic steroids
Primary erythrocytosis (myeloproliferative):
- Polycythemia vera (PV): JAK2 V617F mutation in above 95% of cases; the only primary erythrocytosis; characterized by low EPO (the bone marrow is stimulated by JAK2, not EPO) + elevated RBC + often elevated WBC and platelets + characteristic symptoms (aquagenic pruritus, plethora, thrombosis risk); diagnosed by JAK2 testing and bone marrow biopsy
Normal Red Cell Count Levels
| Category | RBC (million cells/µL) | |---|---| | Normal (men) | 4.7-6.1 | | Normal (women) | 4.2-5.4 | | High (men) | Above 6.1 | | High (women) | Above 5.4 |
When to See Your Care Team
Book a 1:1 consultation with a licensed care team lead for persistently elevated RBC count after ruling out dehydration. The workup starts with hemoglobin, hematocrit, and EPO level. Low EPO with elevated RBC suggests primary erythrocytosis (PV) — test for JAK2 V617F. High or normal EPO with elevated RBC suggests secondary erythrocytosis — investigate for hypoxia (pulse oximetry, sleep study, pulmonary function) or EPO-secreting tumors. Aquagenic pruritus in combination with high RBC and high platelets/WBC is a strong clinical indicator of polycythemia vera.
Frequently Asked Questions
What is aquagenic pruritus and why does it occur in polycythemia vera?
Aquagenic pruritus is intense itching triggered by water contact — not related to water temperature or the mechanical stimulus, but to water itself. It develops or worsens within minutes of water exposure and resolves within 30-60 minutes. In PV, it results from water-induced release of histamine, serotonin, and other mediators from mast cells and basophils (which are dysregulated in the JAK2-mutant clone). It is not caused by the elevated RBC count directly. Treatment options include low-dose aspirin, antihistamines, interferon-alpha, and hydroxyurea (which treats the underlying PV).
Can dehydration cause a high red cell count?
Yes. Dehydration reduces plasma volume (the liquid part of blood), concentrating all blood components including red cells. The RBC count, hemoglobin, hematocrit, and other markers may all appear elevated when the patient is actually not producing more red cells — they are just more concentrated. Rehydration corrects the apparent erythrocytosis. This is called relative (or spurious) erythrocytosis. A key clinical clue: if hemoglobin and hematocrit are high but the patient has no symptoms of polycythemia and has been ill or dehydrated, check after rehydration.
Is a high RBC count from high altitude dangerous?
High-altitude erythrocytosis is a normal, adaptive physiological response — the reduced atmospheric oxygen triggers EPO production, which increases RBC production to carry more oxygen per unit blood volume. At moderate altitudes (1,500-3,000 m), this is beneficial and not dangerous. At very high altitudes (above 4,000 m) or in susceptible individuals, extreme erythrocytosis (hematocrit above 60-65%) can develop, dramatically increasing blood viscosity and causing headache, cognitive impairment, and thrombosis risk (chronic mountain sickness / Monge’s disease). Descent is the treatment.
How is polycythemia vera treated?
PV treatment is risk-stratified. All patients need: low-dose aspirin (reduces thrombotic events) and phlebotomy (removing whole blood to reduce hematocrit to the target of below 45% in men, below 42% in women — this has been shown to reduce thrombotic risk). High-risk patients (age above 60 or prior thrombosis) additionally receive cytoreductive therapy: hydroxyurea is first-line, or ruxolitinib (a JAK1/2 inhibitor) for hydroxyurea-resistant or intolerant patients. Interferon-alpha (ropeginterferon) is preferred in younger patients and in pregnancy (hydroxyurea is teratogenic).
